Preparation of a lipid blend and a phospholipid suspension containing the lipid blend

• US 8,685,441 B2
• Filed: 07/23/2013
• Issued: 04/01/2014
• Est. Priority Date: 01/14/1998
• Status: Expired due to Fees

• Current Assignee: Lantheus Medical Imaging, Inc. (Lantheus Holdings, Inc.)
• Original Assignee: Lantheus Medical Imaging, Inc. (Lantheus Holdings, Inc.)
• Inventors: Hui, Poh K., Bishop, John E., Madrigal, Eleodoro S. Jr.
• Primary Examiner(s): KISHORE, GOLLAMUDI S
• Application Number:
  US13/949,105
• Publication Number:
  US 20130309174A1
• Time in Patent Office: 252 Days
• Field of Search: 424/450
• US Class Current: 424/450
• CPC Class Codes: A61B 8/00 Diagnosis using ultrasonic, sonic or infrasonic waves imaging of objects using sonar G01S15/00
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/24 containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• CPC Class Codes: A61K 49/226 Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels
• CPC Class Codes: A61K 49/227 Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric
• CPC Class Codes: A61K 9/1277 Processes for preparing; Proliposomes

Abstract

The present invention describes processes for the preparation of a lipid blend and a uniform filterable phospholipid suspension containing the lipid blend, such suspension being useful as an ultrasound contrast agent.

Claims

1. A method comprising

(a) formulating a lipid suspension with a perfluorocarbon gas to form an ultrasound contrast agent, and

(b) using the ultrasound contrast agent in an imaging application in a subject, wherein the lipid suspension is made by

(i) contacting phospholipids 1,2-dipalmitoyl-sn-glycero-3-phosphatidic acid, mono sodium salt (DPPA), 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC), and N-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine, mono sodium salt (MPEG5000-DPPE) with a first non-aqueous solvent to form a lipid solution, wherein contacting comprises

(1) sequential addition of the individual phospholipids to the first non-aqueous solvent or

(2) combining the individual phospholipids with each other prior to their addition to the first non-aqueous solvent;

(ii) contacting the lipid solution of (i) with a second non-aqueous solvent which causes the phospholipids to precipitate out as a solid lipid blend;

(iii) collecting the solid lipid blend;

(iv) contacting the solid lipid blend with a third non-aqueous solvent which causes the lipid blend to dissolve to form a lipid blend solution; and

(v) contacting the lipid blend solution with an aqueous solution to yield the lipid suspension.

2. The method of claim 1, wherein the first non-aqueous solvent is a mixture of methanol and toluene.

3. The method of claim 1, wherein the second non-aqueous solvent is methyl t-butyl ether.

4. The method of claim 1, wherein the third non-aqueous solvent is propylene glycol.

5. The method of claim 1, wherein the aqueous solution comprises sodium chloride, glycerin, and propylene glycol.

6. The method of claim 1, wherein

(i) the first non-aqueous solvent is a mixture of methanol and toluene;

(ii) the second non-aqueous solvent is methyl t-butyl ether;

(iii) the third non-aqueous solvent is propylene glycol; and

(iv) the aqueous solution comprises sodium chloride, glycerin and propylene glycol.

7. The method of claim 1, wherein about 0.75 to 1.0 mg of the lipid blend is present per mL of the lipid suspension.

8. The method of claim 1, wherein about 0.75 mg of the lipid blend is present per mL of the lipid suspension.

9. The method of claim 1, wherein the third non-aqueous solvent is heated to a temperature of about 30 to 70°

C. prior to contacting with the solid lipid blend.

10. The method of claim 1, wherein the third non-aqueous solvent is heated to a temperature of about 50 to 55°

C. prior to contacting with the solid lipid blend.

11. The method of claim 1, wherein the ratio of solid lipid blend to third non-aqueous solvent is from about 5-15 mg of solid lipid blend per mL of third non-aqueous solvent.

12. The method of claim 1, wherein the ratio of solid lipid blend to third non-aqueous solvent is about 15 mg of solid lipid blend per mL of third non-aqueous solvent.

13. The method of claim 1, wherein the aqueous solution is heated to a temperature of about 45 to 60°

C. prior to contacting with the lipid blend solution.

14. The method of claim 1, wherein the aqueous solution is heated to a temperature of about 50 to 55°

C. prior to contacting with the lipid blend solution.

15. The method of claim 1, further comprising filtering the lipid suspension through one or two sterilizing filters to form a filtered lipid suspension, prior to formulating with the perfluorocarbon gas.

16. The method of claim 15, wherein the one or two sterilizing filters are 0.2 μ

m filters.

17. The method of claim 15, further comprising dispensing the filtered lipid suspension into a vial, prior to formulating with the perfluorocarbon gas.

18. The method of claim 1, wherein formulating the lipid suspension with the perfluorocarbon gas comprises dispensing the lipid suspension into a vial and exchanging headspace gas of the vial with the perfluorocarbon gas, wherein the lipid suspension is a filtered lipid suspension.

19. The method of claim 1, wherein the perfluorocarbon gas is perfluoropropane.

20. The method of claim 18, wherein the perfluorocarbon gas is perfluoropropane.

21. The method of claim 18, further comprising sterilizing the vial.

22. The method of claim 21, wherein the vial is sterilized at about 126-130°

C. for 1 to 10 minutes.

23. The method of claim 1, wherein

(i) the third non-aqueous solvent is heated to a temperature of about 50-55°

C. prior to contacting with the solid lipid blend; and

(ii) the aqueous solution is heated to a temperature of about 50-55°

C. prior to contacting with the lipid blend solution.

24. The method of claim 6, wherein the lipid suspension comprises about 0.75-1.0 mg of the lipid blend per mL of the lipid suspension.

25. The method of claim 1, wherein the lipid suspension comprises MPEG5000-DPPE, DPPA and DPPC in a mole % ratio of 8 to 10 to 82.

26. The method of claim 7, wherein the lipid suspension comprises MPEG5000-DPPE, DPPA and DPPC in a mole % ratio of 8 to 10 to 82.

27. The method of claim 24, wherein the lipid suspension comprises MPEG5000-DPPE, DPPA and DPPC in a mole % ratio of 8 to 10 to 82.

28. A method comprising:

(a) contacting phospholipids with a first non-aqueous solvent which causes the phospholipids to dissolve and form a lipid solution, wherein the contacting comprises

(i) sequential addition of the individual phospholipids to the first non-aqueous solvent, or

(ii) combining the individual phospholipids with each other prior to their addition to the first non-aqueous solvent, and

wherein the phospholipids are 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC), 1, 2-dipalmitoyl-sn-glycero-3-phosphatidic acid, mono sodium salt (DPPA) and N-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine, mono sodium salt (MPEG5000-DPPE);

(b) contacting the non-aqueous lipid solution of (a) with a second non-aqueous solvent which causes the phospholipids to precipitate out as a solid lipid blend;

(c) collecting the solid lipid blend;

(d) contacting the solid lipid blend with a third non-aqueous solvent which causes the lipid blend to dissolve to form a lipid blend solution;

(e) contacting the lipid blend solution with an aqueous solution to yield a lipid suspension;

(f) formulating the lipid suspension with a perfluorocarbon gas to form an ultrasound contrast agent; and

(g) using the ultrasound contrast agent in an imaging application in a subject.